Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

Abstract Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (I...

Descripción completa

Detalles Bibliográficos

Autores principales:	Mark H. Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J. Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, Mark Atwood
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Adis, Springer Healthcare 2024-03-01
Colección:	Infectious Diseases and Therapy
Materias:	Children Costs and cost analysis Immunization Pneumonia Streptococcus pneumoniae Vaccination
Acceso en línea:	https://doi.org/10.1007/s40121-024-00944-z
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!